Ake P Elhammer, PhD

Ake Elhammer, PhD, is the founder and current CEO of AureoGen Biosciences, Inc. He received his undergraduate and biochemistry Ph.D. degrees at the University of Stockholm, Sweden. Following this, he completed postdoctoral training, sponsored by a NIH Fogarty Fellowship, at the Washington University School of Medicine in St. Louis, MO, before accepting an associate professor position at the Karolinska Institute. Dr. Elhammer took a position as Research Scientist at KABI Gen, a small biotech company in Stockholm, Sweden, working on the development of recombinant Factor VIII, in 1986. In 1987, he moved to the Upjohn Company in Kalamazoo, which subsequently merged into Pharmacia and Upjohn and later Pharmacia, where he worked as a Research Scientist and Senior Research Scientist in drug discovery, several therapeutic areas, and most notably on antibiotics. Following Pharmacia's merger with Pfizer in 2003, Dr. Elhammer founded and became the CEO of AureoGen Biosciences, Inc. AureoGen is a preclinical drug discovery and development company that is focused on the discovery and development of novel antibiotics, Gram positive, Gram negative as well as anti-fungals. AureoGen has been awarded funding from the State of Michigan and WMU BRCC, as well as a number of federal grants from the NIH and the NIST.